NASDAQ:ACON - Nasdaq - US6551873002 - Common Stock - Currency: USD
7.51
-0.13 (-1.7%)
The current stock price of ACON is 7.51 USD. In the past month the price decreased by -46.71%. In the past year, price decreased by -99.75%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
VEEV | VEEVA SYSTEMS INC-CLASS A | 34.42 | 37.02B | ||
DOCS | DOXIMITY INC-CLASS A | 44.26 | 10.63B | ||
WAY | WAYSTAR HOLDING CORP | N/A | 6.37B | ||
CERT | CERTARA INC | 31.49 | 2.29B | ||
SDGR | SCHRODINGER INC | N/A | 1.93B | ||
GDRX | GOODRX HOLDINGS INC-CLASS A | 14.18 | 1.80B | ||
PHR | PHREESIA INC | N/A | 1.45B | ||
TDOC | TELADOC HEALTH INC | N/A | 1.26B | ||
LFMDP | LIFEMD INC - LFMD 8 7/8 PERP | N/A | 1.06B | ||
EVH | EVOLENT HEALTH INC - A | 13.61 | 1.05B | ||
HSTM | HEALTHSTREAM INC | 50.42 | 1.02B | ||
CCLDO | CARECLOUD INC - CCLD 8 3/4 PERP | N/A | 771.92M |
Aclarion, Inc. is a healthcare technology company, which engages in the provision of Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. The company is headquartered in Broomfield, Colorado and currently employs 6 full-time employees. The company went IPO on 2022-04-22. The firm leverages magnetic resonance spectroscopy (MRS), and proprietary biomarkers to optimize clinical treatments. The company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that the Company has demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. The company uses a magnet to apply a pulsed magnetic field to a patient, sensors to detect radio waves that emanate from the resonant vibrations of different chemicals in the body in response to that pulsed magnetic field and a computer to create detailed images of tissue structures in the patient based on those detected chemical signals.
ACLARION INC
8181 Arista Place, Ste 100
Broomfield COLORADO US
Employees: 5
Company Website: https://aclarion.com/
Investor Relations: https://investors.aclarion.com/
Phone: 18332752266
The current stock price of ACON is 7.51 USD. The price decreased by -1.7% in the last trading session.
The exchange symbol of ACLARION INC is ACON and it is listed on the Nasdaq exchange.
ACON stock is listed on the Nasdaq exchange.
8 analysts have analysed ACON and the average price target is 11993.7 USD. This implies a price increase of 159603.06% is expected in the next year compared to the current price of 7.51. Check the ACLARION INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
ACLARION INC (ACON) has a market capitalization of 4.36M USD. This makes ACON a Nano Cap stock.
ACLARION INC (ACON) currently has 5 employees.
The Revenue of ACLARION INC (ACON) is expected to grow by 186.36% in the next year. Check the estimates tab for more information on the ACON EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
ACON does not pay a dividend.
ACLARION INC (ACON) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3500.64).
ChartMill assigns a fundamental rating of 2 / 10 to ACON. The financial health of ACON is average, but there are quite some concerns on its profitability.
Over the last trailing twelve months ACON reported a non-GAAP Earnings per Share(EPS) of -3500.64.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -197.01% | ||
ROE | -250.25% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 80% to ACON. The Buy consensus is the average rating of analysts ratings from 8 analysts.
For the next year, analysts expect an EPS growth of -71.31% and a revenue growth 186.36% for ACON